Posted by Michael Wonder on 29 Jul 2018
FDA approves Perseris (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults
27 July 2018 - Perseris is the first once-monthly subcutaneous risperidone-containing long-acting injectable.
Indivior today announced that the U.S. FDA has approved Perseris, the first once- monthly subcutaneous risperidone-containing, long-acting injectable for the treatment of schizophrenia in adults. Clinically relevant levels were reached after the first injection of Perseris without use of a loading dose or any supplemental oral risperidone.
The efficacy of Perseris was evaluated in a pivotal Phase 3 randomised, double-blind, placebo-controlled, 8-week study of 354 patients.
